Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option...
Main Authors: | Hakim, J, Thompson, J, Kityo, C, Hoppe, A, Kambugu, A, van Oosterhout, J, Lugemwa, A, Siika, A, Mwebaze, R, Mweemba, A, Abongomera, G, Thomason, M, Easterbrook, P, Mugyenyi, P, Walker, A, Paton, N |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2017
|
Similar Items
-
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
by: Hakim, J, et al.
Published: (2017) -
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
by: Kityo, C, et al.
Published: (2010) -
Enhanced Eryptosis Following Exposure to Lopinavir
by: Rosi Bissinger, et al.
Published: (2015-12-01) -
The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
by: Ayşe BATIREL, et al.
Published: (2021-12-01) -
Recurrent oedema associated with the co-formulation of lopinavir and ritonavir Edema recorrente associado à co-formulação de lopinavir e ritonavir
by: Jorge Francisco C. Pinto, et al.
Published: (2004-08-01)